Dr. Mary S. Donnelly

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer.

Dr. Partridge received her MD from Cornell University Medical College in 1995. She completed her residency in internal medicine at the Hospital of the University of Pennsylvania and went on to complete fellowships in medical oncology and hematology at DFCI, MGH and BWH. She also received an MPH from Harvard School of Public Health. She is a medical oncologist who cares for adults with breast cancer, with a particular focus on the unique needs of young patients with breast cancer. She also leads efforts to optimize cancer survivorship care and research at DFCI. She completed fellowships in Medical Oncology and Hematology at DFCI, Massachusetts General Hospital and Brigham and Women’s Hospital. Dr. Partridge is rated as an Elite provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, HER-2 Positive Breast Cancer, Hormone Replacement Therapy (HRT), and Salpingo-Oophorectomy.

Nadine Tung is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Tung is rated as an Elite provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Ovarian Cancer, BRCA Positive Breast Cancer, Salpingo-Oophorectomy, and Hormone Replacement Therapy (HRT).